Given the substantial burden of ICD-related complications, ICD-management after LVAD-implantation should be individualized according to arrhythmic risk, pacing requirements, procedural risk, and patient preferences.
Abstract
Background
The prognostic relevance of implantable cardioverter defibrillator (ICD) in patients with end-stage heart failure (HF) with left ventricular assist device (LVAD) remains controversial.
Objectives
To evaluate the prognostic impact of ongoing use of ICD and associated complications in HF-patients with LVAD-implantation.
Methods
We retrospectively analyzed all consecutive patients (n = 351) who underwent LVAD-implantation and follow up between 2009 and 2021. Patients were categorized according to the presence (n = 254) or absence (n = 97) of ICD. To reduce baseline imbalances between groups, propensity score matching (PSM) was performed, yielding two matched cohorts of 79 patients each. The primary endpoint was a composite of all-cause mortality and heart transplantation. Secondary endpoints included all-cause mortality, heart transplantation, and ICD-related complications.
Results
Median age was 58 [49-65] years, and 85% were male. Median follow-up duration was 3.6 [2.6-5.7] years. The primary endpoint revealed significantly less events in the ICD cohort (44.3% vs. 59.5% (HR 0.6 95%CI [0.40; 0.97], p = 0.035)). The difference was driven by a higher rate of all-cause mortality (22.08% vs. 41.8%, p = 0.008), while the heart transplantation rate was similar (17.7% vs. 21.5%, p = 0.98). ICD-related complications occurred in 20.4% of all ICD-patients, including 27 lead revisions, 8 complete system removals due to infection, 13 inadequate shocks and 4 hematoma evacuations.
Conclusion
ICD therapy was associated with lower mortality in this single-center LVAD-cohort. However, this finding contrasts with recent meta-analytic. Given the substantial burden of ICD-related complications, ICD-management after LVAD-implantation should be individualized according to arrhythmic risk, pacing requirements, procedural risk, and patient preferences.
In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.
Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al.· European Heart Journal· 0 citations
Background: Implantable cardioverter defibrillators (ICDs) are essential for the primary prevention of sudden cardiac death in heart failure (HF); however, appropriate shocks increase mortality and impair quality of life. The electrical risk score (ERS) is an electrocardiographic (ECG)-based composite index with proven...
P. Aladağ, Ilke Erbay, N. E. Güdül et al.· Journal of Clinical Medicine· 0 citations
Implantable cardioverter-defibrillator (ICD) therapy is essential for preventing sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). However, real-world data regarding transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD) systems in patients with HCM remain limited.We retrospectively analyzed 279 p...
Yoshiyasu Aizawa, H. Hayashi, Hiroaki Hirayama et al.· International Heart Journal· 0 citations
Aim.
To identify clinical and instrumental factors associated with clinical outcomes in patients with implanted implantable cardioverterdefibrillators (ICD) / cardiac resynchronization therapy defibrillators (CRTD).
Material and methods.
A singlecenter retrospective registry included clinical and instrumental...
K. N. Kozaeva, E. Rimskaya, G. Tarasovskiy et al.· Journal of Arrhythmology· 0 citations
INTRODUCTION
In patients who survive out-of-hospital cardiac arrest (OHCA), guidelines for implantation of an implantable cardioverter-defibrillator (ICD) are not unequivocal.
METHODS
Patients resuscitated from OHCA of cardiac cause, without a reversible cause and an expected survival >1 year were identified (year 20...
M. Winther-Jensen, B. T. Philbert, M. L. Laursen et al.· Scandinavian Cardiovascular...· 0 citations
Chagas cardiomyopathy was associated with lower composite risk and the wide confidence interval and small population at risk in the late period mean that absence of a detectable difference should not be read as evidence of equivalent risk.
J. P. Guzmán, Pedro Díaz Uberti, Camila Rosello et al.· Frontiers in Cardiovascular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.